

Improved Knoevenagel Condensation Protocol for the Synthesis of Cyanoacrylates and their Anticancer Activity

Santha Kumari Merugu^{1,2}, Hari Babu Bollikolla^{1,3,*}

¹Department of Chemistry, Acharya Nagarjuna University, NNagar, Guntur-522510, AP-India.

²Department of chemistry Govt. College (Autonomous), Rajahmundry-533105, AP-India.

³Department of Nanotechnology, AcharyaNagarjuna University, NNagar, Guntur -522510, AP-India.

*Corresponding author: Hari Babu Bollikolla, email: dr.b.haribabu@gmail.com; Phone: +9163-2346575; +91 8500338866.

Received July 22nd, 2022; Accepted October 25th, 2022.

DOI: <http://dx.doi.org/10.29356/jmcs.v67i1.1835>

Abstract. DIPEAc (diisopropylethylammonium acetate) has been used as a catalyst in the Knoevenagel condensation of aldehydes and ethyl cyanoacetate to produce cyanoacrylate with high yields. The reaction's key characteristics are a shorter reaction time, a large substrate scope, the viability of different functional groups, ease of work-up, and high yields, which provide environmental benefits. Furthermore, the anticancer activity of the synthesized series of cyanoacrylate derivatives was tested against A549, HT-29, and HepG2 cell lines.

Keywords: Ethyl cyanoacetate; diisopropylethylammonium acetate (DIPEAc); cyanoacrylate; Knoevenagel condensation; anticancer activity.

Resumen. El acetato de diisopropiletilamonio (DIPEAc) se empleó como catalizador en la reacción de condensación de Knoevenagel empleando aldehídos y cianoacetato de etilo para producir cianoacrilatos en rendimientos elevados. Algunas características de esta aplicación es el que requiere tiempos cortos de reacción, se puede practicar en una amplia gama de sustratos, tolera varios grupos funcionales, el trabajo de la reacción es sencillo y tiene elevados rendimientos, lo que es compatible con el medio ambiente. Los productos obtenidos fueron probados con las líneas celulares A549, HT-29 y HepG2.

Palabras clave: Cianoacetato de etilo, acetato de diisopropiletilamonio; cianoacrilato, Condensación de Knoevenagel, actividad anticancerígena.


Introduction

In recent decades, the development of homogeneous catalyzed transformations has played a critical role in organic synthesis. Ionic liquids have been used as catalysts or reagents in homogeneous medium in organic synthesis in recent years [1-3]. Ionic liquids have created numerous opportunities for their use in the synthesis of key motifs, which has generated tremendous interest from an academic, industrial, and specifically in the synthesis of pharmaceutical compounds [4]. Ionic liquid solubility can be altered by modifying cations and anions to improve catalytic activity and solubility differences in an aqueous medium and less polar solvent system. The ionic liquid catalyst/reagent can be separated from the reaction at the end and reused or regenerated [5-8].

Room temperature ionic liquid supported (ILs) catalysts are used in homogeneous organic synthesis to achieve higher catalytic activity and selectivity than a homogeneous parent catalytic system. Advantages of ionic liquids, which have been designed to be a soluble polar organic solvent by incorporating a nonpolar organic solvent that can be recovered and reused. Ionic liquids have a number of advantages. 1) ionic character and high polarity 2) ionic liquid supported catalysts outperform solid supported catalysts in terms of loading capacity. 3) excellent selectivity.

In organic synthesis, the Knoevenagel condensation reaction is the most powerful tool for forming a C-C bond. Emil Knoevenagel developed a valuable method [9] for Knoevenagel condensation between formaldehyde and diethylmalonate with diethylamine as a catalyst in 1894. Later several improvements have been reported by different research groups such as piperidine [10], L-Proline [11], β -alanine [12], TBAB [13], [MeHMTA]BF₄ [14], resin poly(propylene imine)dendrimer [15], nano-Fe₃O₄ [16], 2,4,6-trichloro-1,3,5-triazine (TCT) [17], [bmim(NTf₂)] [18], Al₂O₃-SiO₂ [19] and other conditions [20].

On the other hand, cyanoacrylate is having several applications, which undergoes several transformations with different reagents to produce variety of biologically active scaffolds, including 1,5-disubstituted pyrazoles [21], substituted tetrazoles [22], 2-amino dihydropyridine derivatives [23], 2-amino pyrrole derivatives [24], pyrimidine-5-carbonitrile [25], benzothiazole derivatives [26] (Scheme 1).



Scheme 1. Applications of cyanoacrylates.

However, numerous methods for Knoevenagel condensation are available in the literature, with several drawbacks such as strong acidic, hazardous, and expensive reagents, toxic nature, longer reaction time, and lower yields. Many researchers have worked seriously to develop an efficient cyanoacrylate synthesis using Knoevenagel condensation, which is still needed.

In this paper based on our research programme [27,28], we report an efficient Knoevenagel condensation between ethyl cyanoacetate and aromatic aldehyde in the presence of diisopropylethylammonium acetate (DIPEAc) for the formation of cyanoacrylates in good to excellent yields. Diisopropylethyl ammonium acetate (DIPEAc) was used as an ionic liquid catalyst for various synthetic applications, including the synthesis of Biginelli dihydropyrimidines and dihydrothiophenes by Gill *et al.* [29,30]

Experimental

Materials and methods

All the reagents and solvents used in the synthesis are laboratory grade. The purity of the compounds was checked by TLC (silica gel 60 F254), which were purchased from merck Inc and visualized under UV light. Melting points are analyzed for all synthesized analogues by open tube capillary tube by using Meltemp equipment. The mass spectrums were obtained on Agilent (1100 series) instrument. The Perkin Elmer FT-IR spectrometer was used for IR spectra.

¹HNMR & ¹³CNMR were recorded with BRUKER-400 MHz spectrometer using CDCl₃/DMSO solvent. All the chemical shifts were reported in δ (ppm), using tetramethylsilane (TMS) as internal standard. Multiplicities are recorded by the following abbreviation: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; bs broad singlet; bd, broad doublet; J, coupling constant (hertz).

General procedure for synthesis of Cyano acrylate derivatives

Diisopropylethylammonium acetate (0.1 mmol) was added to a mixture of aromatic aldehydes **1a-II** (1 mmol), ethylcyanoacetate **2** (1 mmol) in hexane (10 ml) and heated at 65-70 °C. After 3-6 hours, the progress of reaction was monitored by TLC (hexane:Ethylacetate, 8:2). After completion of the reaction, was cooled to 40-45 °C. Separated the layers and bottom (product) layer was concentrated under vacuum, resulting material was purified by suitable solvents to give desired products are given below (**3a-3l**).

Ethyl-2-cyano-3-phenylacrylate (3a). [1] solid (91 %) mp 48-51 °C; IR (KBr) Cm⁻¹: 2982, 2220, 1716, 1600, 1440; ¹HNMR (400 MHz, CDCl₃): δ 1.41 (t, *J* = 7.4 Hz, 3H), 4.36-4.41 (q, *J* = 7.4 Hz, 2H), 7.50-7.60 (m, 3H), 8.02 (d, *J* = 7.4 Hz, 2H), 8.40 (s, 1H); ¹³CNMR (100 MHz, CDCl₃): δ 14.2, 62.8, 103.0, 115.5, 130.1, 131.1, 131.5, 133.4, 155.1, 162.5. Anal Calc for C₁₂H₁₁NO₂: C, 71.63; H, 5.51; N, 6.96 %; found: C, 71.59; H, 5.48 ; N, 6.84 %.

Ethyl-2-cyano-3-(2-nitrophenyl)acrylate (3b). [3] solid (90 %) mp 119-123 °C; IR (KBr) Cm⁻¹: 2986, 2218, 1718, 1582, 1485; ¹HNMR (400 MHz, CDCl₃): δ = 1.42 (t, *J* = 7.4 Hz, 3H), 4.39-4.45 (q, *J* = 7.4 Hz, 2H), 7.70-7.74 (m, 1H), 7.80-7.87 (m, 2H), 8.28 (d, *J* = 7.4 Hz, 2H), 8.72 (s, 1H); ¹³CNMR (100 MHz, CDCl₃): δ = 14.1, 63.1, 106.7, 113.7, 125.3, 128.1, 130.5, 132.1, 134.4, 147.3, 152.9, 161.0; Anal Calc for C₁₂H₁₀N₂O₄: C, 58.54; H, 4.09; N, 11.38 %; found: C, 58.50; H, 3.99; N, 11.32 %.

Ethyl-2-cyano-3-(3-nitrophenyl)acrylate (3c). [3] solid (91 %) mp 129-132 °C; IR (KBr) Cm⁻¹: 2929, 2252, 1738, 1600, 727; ¹HNMR (400 MHz, CDCl₃): δ = 1.42 (t, *J* = 7.4 Hz, 3H), 4.40-4.45 (m, 2H), 7.72-7.76 (m, 1H), 8.32 (s, 1H), 8.39-8.42 (m, 2H), 8.70 (s, 1H); ¹³CNMR (100 MHz, CDCl₃): δ = 13.5, 62.7, 106.3, 113.9, 125.3, 126.4, 130.0, 132.5, 134.6, 148.2, 151.2, 160.9; Anal Calc for C₁₂H₁₀N₂O₄: C, 58.54; H, 4.09; N, 11.38 %; found: C, 58.51 ; H, 4.01; N, 11.29 %.

Ethyl-2-cyano-3-(4-nitrophenyl)acrylate (3d). [3] solid (93 %) mp 161-165 °C; IR (KBr) Cm⁻¹: 2856, 2196, 1738, 1519, 854; ¹HNMR (400 MHz, CDCl₃): δ = 1.32 (t, *J* = 7.2 Hz, 3H), 4.32-4.38 (m, 2H), 8.23-8.26 (m, 2H), 8.42-8.40 (m, 2H), 8.56 (s, 1H); ¹³CNMR (100 MHz, CDCl₃): δ = 14.4, 63.2, 107.1, 115.4, 124.6, 132.1, 137.7, 149.7, 153.1, 161.6; Anal Calc for C₁₂H₁₀N₂O₄: C, 58.54; H, 4.09 ; N, 11.38 %; found: C, 58.48; H, 4.03; N, 11.35 %.

Ethyl-2-cyano-3-(2-Chlorophenyl)acrylate (3e). [1,2] solid (88 %) mp 45-48 °C; IR (KBr) Cm⁻¹: 2981, 1716, 1688, 1441, 755; ¹HNMR (400 MHz, CDCl₃): δ = 1.41 (t, *J* = 7.2 Hz, 3H), 4.38-4.43 (m, 2H), 7.41-7.51 (m, 3H), 8.22-8.24 (m, 1H), 8.68 (s, 1H); ¹³CNMR (100 MHz, CDCl₃): δ = 14.0, 62.9, 106.1, 114.8, 127.4, 129.8, 130.3, 136.4, 151.2, 161.8; Anal Calc for C₁₂H₁₀ClNO₂: C, 61.16; H, 4.28 ; N, 5.94 %; found: C, 61.09 ; H, 4.23; N, 5.89 %.

Ethyl-2-cyano-3-(4-Chlorophenyl)acrylate (3f). [1] solid (94 %) mp 88-90 °C; IR (KBr) Cm^{-1} : 2986, 2218, 1718, 1582, 1485, 828; ^1H NMR (400 MHz, CDCl_3): δ = 1.40 (t, J = 7.2 Hz, 3H), 4.36-4.41 (m, 2H), 7.48(d, J = 7.2 Hz, 2H), 7.93 (d, J = 7.2 Hz, 2H), 8.19 (s, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ = 14.1, 62.8, 103.5, 115.2, 129.6, 129.9, 139.5, 153.3, 162.1; Anal Calc for $\text{C}_{12}\text{H}_{10}\text{ClNO}_2$: C,61.16; H,4.28; ; N,5.94 %; found:C, 61.08; H, 4.19; N, 5.87 %.

Ethyl-2-cyano-3-(4-methoxyphenyl)acrylate (3g). [1,2] solid (96 %) mp 77-80 °C; IR (KBr) Cm^{-1} : 2988, 2213, 1712, 1583, 1177; ^1H NMR (400 MHz, CDCl_3): δ = 1.37 (t, J = 7.2 Hz, 3H), 3.87 (s, 3H), 4.32-4.37 (m, 2H), 6.97 (d, J = 7.2 Hz, 2H), 7.98 (d, J = 7.2 Hz, 2H), 8.15 (s, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ = 14.1, 55.8, 62.4, 99.4, 114.7, 116.2, 124.3, 133.6, 154.3, 163.1, 163.7; Anal Calc for $\text{C}_{13}\text{H}_{13}\text{NO}_3$: C,67.52; H,5.67 ; N,6.06 %; found:C, 67.49; H, 5.61; N, 6.03 %.

Ethyl-2-cyano-3-(4-benzyloxyphenyl)acrylate (3h). [5] solid (93 %) mp 146-149 °C; IR (KBr) Cm^{-1} : 2922, 2218, 1714, 1586, 1177, 903; ^1H NMR (400 MHz, CDCl_3): δ = 1.33 (t, J = 8.0 Hz, 3H), 4.34-4.39 (m, 2H), 5.15 (s, 2H), 7.04-7.08 (m, 2H), 7.34-7.45 (m, 5H), 8.01 (d, J = 4.0 Hz, 2H), 8.17 (s, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ = 14.1, 62.4, 70.3, 99.4, 115.5, 116.1, 124.5, 127.4, 128.3, 128.7, 133.6, 135.7, 154.3, 162.8; Anal Calc for $\text{C}_{19}\text{H}_{17}\text{NO}_3$: C,74.25; H,5.58 ; N,4.56 %; found:C, 74.18; H, 5.51; N, 4.53 %.

(4E)-Ethyl-2-cyano-5-phenylpenta-2,4-dienoate (3i). [6] solid (96 %) mp 113-115 °C; IR (KBr) Cm^{-1} : 2981, 2248, 1737, 1580, 1449, 1236; ^1H NMR (400 MHz, CDCl_3): δ = 1.28 (t, J = 7.2 Hz, 3H), 4.24-4.30 (m, 2H), 7.18-7.25 (m, 1H), 7.46-7.48 (m, 3H), 7.69-7.72 (m, 3H), 8.17 (d, J = 7.2 Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ = 14.4, 62.4, 103.7, 115.0, 123.0, 129.1, 129.6, 131.7, 135.0, 150.5, 156.3, 162.2; Anal Calc for $\text{C}_{14}\text{H}_{13}\text{NO}_2$: C,73.99; H,5.77 ; N,6.16 %; found:C, 73.91; H, 5.63; N, 6.09 %.

Ethyl-2-cyano-3-p-tolylacrylate (3j). [1, 2] solid (92 %) mp 88-92 °C; IR (KBr) Cm^{-1} : 2983, 2251, 1742, 1600, 1445; ^1H NMR (400 MHz, CDCl_3): δ = 1.39 (t, J = 7.4 Hz, 3H), 2.46 (s, 3H), 4.34-4.40 (m, 2H), 7.18-7.30 (d, J = 8.0 Hz, 1H), 7.86 (d, J = 8.0 Hz, 1H), 8.22 (s, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ = 13.8, 21.4, 62.0, 101.1, 115.3, 128.5, 129.5, 130.8, 144.2, 154.5, 162.3. Anal Calc for $\text{C}_{13}\text{H}_{13}\text{NO}_2$: C,72.54; H,6.09 ; N,6.51 %; found:C, 72.38; H, 6.04; N, 6.39 %.


Ethyl-2-cyano-3-(furan-2-yl)acrylate (3k). [3] solid (90 %) mp 83-85 °C; IR (KBr) Cm^{-1} : 2984, 2252, 1741, 1613, 1462; ^1H NMR (400 MHz, CDCl_3): δ = 1.38 (t, J = 7.2 Hz, 3H), 4.33-4.38 (m, 2H), 6.66-6.67 (m, 1H), 7.39-7.40 (m, 1H), 7.75-7.76 (m, 1H), 8.01 (s, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ = 14.1, 62.5, 98.7, 113.8, 115.2, 121.5, 139.4, 148.1, 148.7, 162.5; Anal Calc for $\text{C}_{10}\text{H}_9\text{NO}_3$: C,62.82; H,4.74 ; N,7.33 %; found:C, 62.63; H, 4.56; N, 7.09 %.

Ethyl-2-cyano-3-(thiophen-2-yl)acrylate (3l)- [4] solid (91 %) mp 93-96 °C; IR (KBr) Cm^{-1} : 3085, 2919, 2217, 1715, 1596, 1216; ^1H NMR (400 MHz, CDCl_3): δ = 1.39 (t, J = 7.2 Hz, 3H), 4.39-4.34(m, 2H), 7.22-7.26 (m, 1H), 7.78-7.84 (m, 2H), 8.35 (s, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ = 14.1, 62.5, 99.3, 115.7, 128.5, 135.1, 137.1, 146.6, 162.6; Anal Calc for $\text{C}_{10}\text{H}_9\text{NO}_2\text{S}$: C,57.95; H,4.38 ; N,6.76; S, 15.47 %; found:C, 57.88; H, 4.31; N, 6.59; S 15.36 %.

Mechanism

Scheme 2 proposes a plausible mechanistic pathway based on controlled experiments and previous literature reports. In step 1, the DIPEAc catalyst deprotonates a proton from the active methylene compound to form carbanion. The nucleophilic attack of a carbanion on the carbonyl carbon of an aldehyde to form a C-C bond with an alcohol compound. The anion of DIPEAc attacks alcohol to produce the dehydrated product cyanoacrylates. In this reaction mechanism, the counter anions play an important role in activating the nucleophile of the active methylene compound to produce carbanion, while the cation acts as an activator for the electrophiles of the carbonyl compound by increasing C=O bond polarity via hydrogen bond formation.

Finally, the Knoevenagel condensed product is obtained by dehydrating or expelling water molecules from the structure.



Scheme 2. Plausible mechanistic pathway.

The synthesized compounds (**3a-3l**) were tested for cytotoxic activity against human cancer cell lines A549 (Human lung adenocarcinoma cell line), HepG2 (Human liver cancer cell line), and HT-29 (Human colorectal adenocarcinoma cell line) using our previously followed protocol [31], and IC_{50} values were calculated using a linear regression equation from dose response data obtained at different concentrations. Doxorubicin (CAS 23214-92-8) was chosen as the reference standard medication due to its well-known therapeutic efficacy in a wide range of malignancies. The cyanoacrylates (**3a-l**) synthesised were discovered to have a 10-65 % inhibitory capacity against the proliferation of cancer cell lines. A dose-response study was conducted on chemicals that inhibited cancer cell growth by 50 % or more, and their IC_{50} values were examined. A comparative data of the IC_{50} values for the cyano acrylate are presented in Table 1.

Table 1. Results of anticancer activity on selected cell lines using different concentration (0-200 µg/mL).

S. No.	Compound	Activity IC ₅₀ (µg/mL)		
		A549	HepG2	HT-29
1	3a	>200	>200	179.5± 16.4
2	3b	>200	>200	130.8± 22.5
3	3c	175.8± 16.3	192.5± 17.1	169.4± 10.3
4	3d	183.4± 14.3	>200	172.7± 15.1
5	3e	169.6 ± 11.2	>200	131.6± 9.7
6	3f	>200	171.3± 13.4	170.7± 15.3
7	3g	>200	178.5± 20.7	>200
8	3h	>200	163.5± 8.7	179.5± 18.1
9	3i	77.78± 5.8	158.5± 14.2	117.6± 10.4
10	3j	>200	170.1± 12.5	>200
11	3k	>200	>200	>200
12	3l	>200	184± 13.8	>200
Reference	Doxorubicin	1.1 ± 0.4	0.8 ± 0.3	1.3 ± 0.6


Cinnamyl (**3i**) and 4-methoxyphenyl (**3g**), 4-benzyloxyphenyl (**3h**), and 4-chlorophenyl (**3f**) compounds were discovered to have good cytotoxic activity against HT-29 and HepG2 cancer cell lines. All para substituted phenyl (**3g**, **3h**, **3f**) demonstrated increased anticancer activity. The compounds **3i** and **3e** demonstrated more potent cancer activity, with IC₅₀ values of 77.78 and 169.6 µg/mL, respectively. Similarly, the compounds with phenyl (**3a**), 2-nitrophenyl (**3b**), 4-nitrophenyl (**3d**), and 2-chlorophenyl (**3e**) substitutions demonstrated improved cytotoxicity against HT-29 and HepG2 cancer cell lines. However, substitution on the *para*-position increased activity more than substitution on the *ortho*- and *meta*-position. In respect of colorectal cancer cell line HT-29 and liver cancer cell line HepG2, cinnamyl analogue **3i** proved to be the most potent compound with superior anticancer activity, suggesting that conjugated cyanoacrylate is a good platform for further optimization to develop an anti-cancer activity. It is anticipated that SAR study may help in designing future analogs for promising anticancer molecule.

In conclusion, we established an efficient Knoevenagel condensation protocol for the synthesis of cyanoacrylates with a wide range of substrates to demonstrate the protocol's generality. We believe that this methodology, which provides superior benefits for the construction of cyanoacrylates using commercially available and inexpensive materials, will gain widespread acceptance in the synthetic organic chemistry, medicinal, and pharmaceutical industries. The anti-cancer activity of the synthesized compounds was tested on the cancer cell lines A549, HepG2, and HT29. The compounds **3i** and **3e** demonstrated more potent cancer activity, with IC₅₀ values of 77.78 and 169.6 g/mL for various cancer cell lines, highlighting the role of substituent position in the activity of the compounds. These potential compounds and analogues could be further optimized and developed as a novel class of anti-cancer agents.

Results and conclusions

We began with benzaldehyde (1 mmol) and ethylcyanoacetate (1 mmol) as model substrates to achieve optimal conditions for Knoevenagel reaction. The reaction carried out in MDC without a catalyst yielded 5 % product at reflux temperature and there was no further progress in the reaction with increased time. We tested by changing the catalyst, temperature, and solvents, and the results are summarized in Table 2. We tested various catalysts, including triethylamine, piperidine, piperidine acetate, triethylamine hydrochloride, phenylalanine, and diisopropylethyl ammonium acetate, to obtain the preferred product (DIPEAc). We repeated the same reaction with tetraethylammonium tetrafluoroborate and tetrabutylammonium chloride as catalysts

and obtained 62 % and 57 % of the desired product, respectively. Among the tested conditions, the product was obtained in excellent yield in the presence of diisopropylethyl ammonium acetate (DIPEAc).



Scheme 3. Optimization of reaction condition.

Table 2. Comparison of different catalyst efficiency for the synthesis.

S. No.	Catalyst	medium	Time	Yield of compound 3
1	Without catalyst	MDC	12h	5 %
2	Triethylamine	MDC	12h	60%
2	Triethylamine hydrochloride	MDC	10 h	64%
3	Piperidine	MDC	8h	72%
4	Piperidine acetate	MDC	10h	58%
5	Phenylalanine	THF	12h	52%
6	Diisopropylethyl ammonium acetate	MDC	8 h	76%
7	Diisopropylethyl ammonium acetate	Hexane	3h	91%
8	Tetraethylammonium tetrafluoroborate	Hexane	7h	62%
9	Tetrabutylammonium chloride	Hexane	7h	57%

Reagents conditions: a) Reaction aldehyde (1 mmol), ethylcyanoacetate (1mmol) in DIPEAc(0.1 mmol)
b) stirred at 70 °C

Inspired by this preliminary success, we carried out the reaction with varying amounts of DIPEAc ranging from 2 % to 20 %. (Table 3). At reflux temperature, 10% DIPEAc yields 91 % of the **3a**. Increasing the amount of DIPEAc did not improve the reaction yield.

So, 10 mol % DIPEAc was tested in various solvents, including MDC, hexane, ethanol, methanol, DMF, acetonitrile, THF, and diisopropyl ether. In hexane, the reaction proceeds smoothly and with a high yield. At reflux temperature, the Diisopropyl ether reaction proceeds with a lower yield than the MDC, ethanol, methanol, DMF, acetonitrile, and THF reactions. Based on the above optimization, we have reached a final concentration of 10 mol % DIPEAc in hexane solvent at reflux temperature, yielding the desired product with 91 % yield.












Table 3. Comparison of different amount catalyst.













S. No.	Catalyst quantity	Time	Yield
1	2%	12 h	55%
2	5%	10 h	78%
3	10%	3 h	91%
4	15%	3h	91%
5	20%	3h	90%

Similar reaction conditions were successfully used to produce high yields of various substituted cyanoacrylates (**3a-o**) (Table 4). With various substituted aromatic aldehydes (**2a-2o**), electron releasing groups

such as -OMe, -OBn, and 4-Me formed corresponding cyanoacrylates with excellent yields of 96 %, 93 %, and 92 %, respectively. Under these optimized conditions, halogen containing (-Cl) aromatic aldehyde performed well (Table 4). Electron withdrawing groups and hetero aryl aldehydes provide up to 95 % yield of cyanoacrylates. With the ideal condition in hand, we applied the same conditions to various aldehydes, including cinnamaldehydes, to produce the desired product up to 90 % yield (Table 4).

Table 4. Substrate scope of Cyanoacrylate.

S. No.	Aldehyde	product	Yield (%)
1	 2a	 3a	91
2	 2b	 3b	90
3	 2c	 3c	91
4	 2d	 3d	93
5	 2e	 3e	88
6	 2f	 3f	94

7	 <p>CHO OCH₃ 2g</p>	 <p>NC H₃CO 3g</p>	96
8	 <p>CHO OBn 2h</p>	 <p>NC BnO 3h</p>	93
9	 <p>CHO 2i</p>	 <p>NC 3i</p>	96
10	 <p>CHO Me 2j</p>	 <p>NC Me 3j</p>	92
11	 <p>CHO 2k</p>	 <p>NC 3k</p>	90
12	 <p>CHO 2l</p>	 <p>NC 3l</p>	91

Reagents conditions: a) Reaction aldehyde (1 mmol), ethylcyanoacetate (1mmol) in DIPEAc(0.1 mmol)b) stirred at 70 °C

References

1. Lombardo, M.; Pasi, F.; Easwar, S.; Trombini, C. *Adv. Synth. Catal.* **2007**, 349, 2061–2065.
2. Zhou, L.; Wang, L. *Chem. Lett.* 2007,36, 628-629.
3. Siyutkin D.E.; Kucherenko A.S.; Struchkova M.I.; Zlotin S.G. *Tetrahedron Lett.* **2008**, 49, 1212-1216.

4. Ni, B.; Headley, A.D. *Chem. Eur. J.* **2010**, 16, 4426-4436.
5. Handy, S.T. *J. Org. Chem.* **2006**, 71, 4659-4662.
6. Anjaiah, S.; Chandrasekhar, S.; Gree, R. *J. Mol. Catal. A: Chem.* **2004**, 214, 103-106.
7. Vijaya Durga, T.; Rambabu, A.; Srinivas Reddy, M.; Hari Babu, B. *Asian. J. Chem.* **2017**, 29, 1313-1316.
8. Sowjanya, P.; Srinivasa Rao, V.; Srinivas Reddy, M.; Md Nayeem, S.K.; Haribabu, B. *J. Chem. Thermodyn.* **2021**, 154, 106330.
9. Knoevenagel, E. *Ber. Dtsch. Chem. Ges.* **1894**, 27, 2345-2346.
10. Rodionow, W. M. *J. Am. Chem. Soc.* **1929**, 51, 847-852.
11. Wang, Y.; Shang, Z.; Wu, T.; Fan, J.; Chen, J.; *J. Mol. Catal. A: Chem.* **2006**, 253, 212-221.
12. Zhu, L.; Lei, N.; Miao, Z.; Sheng, C.; Zhuang, C.; Yao, J.; Zhang, W. *Chin. J. Chem.* **2012**, 30, 139-143.
13. Gupta, M.; Wakhloo, B.P. *ARKIVOC*, **2007**, 94-98.
14. Sanjoy, K.; Nimalini, M.; Warjeet, S.L. *Indian J. Chem., Sect. B: Org. Chem. Incl. Med. Chem.* **2015**, 54B, 1157-1161.
15. Rajesh Krihnan, G.P.; Sreekumar, K. *Tetrahedron Lett.* **2014**, 55, 2352-2354.
16. Zhang, Q.; Ma, X.M.; Wei, H.X.; Zhao, X.; Luo, J. *RSC Adv.* **2017**, 7, 53861-53870.
17. Wan, J.P.; Jing, Y.; Liu, Y.; Sheng, S.; *RSC Adv.* **2014**, 4, 63997-64000.
18. de Paula, B.R.S.; Zampieri, D.S.; Zukerman-Schpector, J.; Tiekink, E.R.T.; Rodrigues, J.A.R.; Moran, P. J.S. *J. Braz. Chem. Soc.* **2012**, 23 (5), 825-830.
19. Kolahdoozan, M.; Kalbasi, R.J.; Shahzeidi, Z.S.; Zamani, F. *Journal of Chemistry*. **2013**, <https://doi.org/10.1155/2013/496837>.
20. Beurden, K.V.; de Koning, S.; Molendijk, D.; Schijndel, J.V. *Green Chem. Lett. Rev.* **2020**, 13, 349-364.
21. Ashok, S.P.; Aravind, S.B.; Devkate, S.S. *Asian. J. Chem.* **2020**, 32, 575-579.
22. Ruger, N.; Fassauer, G.M.; Bock, C.; Emmrich, T.; Bodtke, A.; Link, A. *Mol. Diversity*. **2017**, 21(1), 9-27.
23. Naveen, S.; Lakshmi, S.; Dinesh, M.; Alpesh, P.; Anamik, S.; Sridhar, M.A.; Prasad, J.S. *J. Chem. Crystallogr.* **2007**, 37, 733-738.
24. Guchhait, S.K.; Sisodiya, S.; Saini, M.; Shah, Y.V.; Kumar, G.; Daniel, D.P.; Hura, N.; Chaudhary, V. *J. Org. Chem.* **2018**, 83, 5807-5815.
25. (a)Porter, D.W.; Bardley, M.; Brown, Z.; Charlton, S.J.; Cox, B.; Hunt, P.; Janus, D.; Lewis, S.; Oakey, P.; Connor, D.O.; Reilly, J.; Smith, N.; Press, N. *J. Bioorg. Med. Chem. Lett.* **2014**, 24, 3285-3290. (b)Youseff, M.; Mohamed, H.M.; Czezowski, C; Ata, A.; Abd-El-Aziz, A.S. *Heterocycles*. **2006**, 68(2), 347-355.
26. Surendarnathareddy, O.; Surya Narayana, Ch.V.; Sharmila, N; Ramana, G.V.; Anuradha, V.; Hari Babu, B. *Lett. Drug Des. Discovery*. **2013**, 10, 699-705.
27. Ramesh, N.; Gangadhara Rao, M.; Tirumala, M.; Uma, M.V.; Hari Babu, B. *Asian. J. Chem.*, **2016**, 28, 1321-1324.
28. Jadhav, C.K.; Nipate, A.S.; Chate, A.V.; Songire, V.D.; Patil, A.P; Gill, C.H. *ACS Omega*, **2019**, 4, 22313-22324.
29. Jadhav, C.K.; Nipate, A.S.; Chate, A.V.; Dofe, V.S.; Sangishetti, J.N.; Khedkar, V.M.; Gill, C.H. *ACS Omega*. **2020**, 45, 29055-29067.
30. Surendarnathareddy, O.; Baby Ramana, M.; Vijaya Durga, T.; Basavaiah, C.; Rajya Lakshmi, C.; Mokesh, R.G.; Vijaya, K.; Hari Babu, B. *ChemistrySelect*. **2020**, 5, 8194-8197.